Where does Entrada Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Entrada Therapeutics, Inc. ranks #40,052 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Entrada Therapeutics, Inc. hold?

Entrada Therapeutics, Inc. holds 6 US utility patents granted between 2020 and 2025, spanning 8 technology areas.

What is Entrada Therapeutics, Inc.'s Innovation Score?

Entrada Therapeutics, Inc. has an Innovation Score of 36.2 out of 100 (top 47% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Entrada Therapeutics, Inc. focus on?

Entrada Therapeutics, Inc.'s top technology area is C12Y (Enzymes) with 5 patents. Grants appear in 8 CPC subclasses total.

Is Entrada Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Entrada Therapeutics, Inc..

What does claim depth mean for Entrada Therapeutics, Inc.'s patents?

Entrada Therapeutics, Inc.'s patents average 29.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Entrada Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Entrada Therapeutics, Inc.

USPTO PatentsView assignee record - 6 granted patents across 8 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Y (Enzymes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Entrada ranks #40,052 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 8 technology areas.

#40,052
of 49,997 US assignees by volume: Top 47%
by Innovation Score (36.2/100): 29.3
avg claims per patent

USPTO PatentsView assignee plate

Corpus R40052 · US Corporation #40,052 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 6 grants
LOWER-Q #40,052/49,997
PHOTO-FINISH Ensco Services
CPC-NARROW C12Y · 8 areas
INNOV-THIN 36.2/100
CLAIMS-DENSE 29.3 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2020–2025 · 6y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Ensco Services Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Entrada Therapeutics · this assignee

36
3D Lighting… · lowest

7

What this shows Entrada's Innovation Score is 36.2/100 (top 47% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Entrada's grants concentrate

Entrada Therapeutics, Inc. is a focused PatentsView assignee: 8 CPC subclasses with 83.3% of grants classified under C12Y (Enzymes). Peak complete grant year is 2020 (2 grants) versus a trough of 1 in 2021. By volume, Entrada sits between Ensco Services Limited and Epineuron Technologies Inc..

Entrada's three-year grant acceleration

Entrada Therapeutics, Inc. shows 2 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Ensco Services

6
Ensign Drilling

6
Enteroptyx

6
Enterprises Inter…

6
Enviro Tech Chemi…

6
Environmental Lig…

6
Eovations

6
Epineuron

6
Entrada Therapeut… ◀

6

What this shows Entrada holds 6 patents at rank #40,091, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Entrada

By rank, the assignees closest to #40,091 in granted patent volume.

Leaders in C12Y (Enzymes)

Other assignees with the most granted patents in Entrada's primary technology class.

Entrada's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

36 Top 47% higher than 53% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Entrada Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	2	33.3%
2021	1	16.7%
2022	1	16.7%
2024	1	16.7%
2025partial year	1	16.7%

Which technologies does Entrada Therapeutics, Inc. patent most?

C12Y - Enzymes 5

C07K - Peptides 5

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 5

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 2

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 2

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 1

C07D - Heterocyclic Compounds 1

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 1

Top 8 of 8 technology areas

Where it ranks

Overall rank by patents

#40,052

of 49,997 tracked assignees

Innovation Score

36.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Entrada Therapeutics, Inc.'s patent record in context - here's where to go next.

Entrada Therapeutics, Inc.'s lead technology class is C12Y (Enzymes), 83.3% of its portfolio - see every assignee active in that class. Explore C12Y
Ranked #40,052 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Entrada Therapeutics, Inc. against Ensco Services Limited, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 36.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.